Cantargia Ab · OMXSTO:CANTA
Cantargia Ab — DNB Nordic Healthcare Conference 2021
14 slides from Cantargia Ab's conference presentation, Dec 16, 2021
Slide 1: We want to save patients with severe cancer and autoimmune diseases
We want to save patients with severe cancer and autoimmune diseases Clinical investigations with nadunolimab to our proprietary target Göran Forsberg, CEO Dec 2021
Slide 2: Safe Harbour Statement
Safe Harbour Statement Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known an
Slide 3: Cantargia – Opportunity to save lives and create value
Cantargia – Opportunity to save lives and create value Type of Discovery Preclinical Clinical Clinical Clinical Commercial Project Disease treatment phase phase Phase I Phase II Phase III phase Gemcitabine/nab-paclitaxel Pancreatic cancer 1st line ➢ Potentially more effective FOLFIRINOX treatment ag
Slide 4: Cantargia highlights
Cantargia highlights UNIQUE IMMUNOTHERAPY ANTIBODY CAN04 IN PHASE IIA CLINICAL DEVELOPMENT • First in class antibody with broader MOA than competitors Current owners (30 Sep 2021) • Positive clinical interim data in pancreatic cancer and NSCLC VISION OF BECOMING AN IMPORTANT PART IN FUTURE CANCER TR
Slide 5: CAN04 – Mechanism of action through IL1RAP binding
CAN04 – Mechanism of action through IL1RAP binding ADCC – Reduced activation Reduced Tumor cell death and infiltration of angiogenesis immunosuppressive cells • The IL-1 system contribute to cancer development by promoting chronic inflammation and resistance to established therapies • CAN04 blocks b
Slide 6: CAN04 – IL1RAP binding gives differentiated and superior MOA
CAN04 – IL1RAP binding gives differentiated and superior MOA Cancer context IL-1α IL-1β comment Localization • Cellbound and soluble • Soluble • IL-1α trigger and IL-1β • Cancer cells and stroma enhance inflammation • Often work in pair Function • Stimulates inflammation - IL1R1 -forming complex wit
Slide 7: CAN04 broad mechanism uniquely enhance docetaxel antitumor activity
CAN04 broad mechanism uniquely enhance docetaxel antitumor activity ✱ 100 → CAN04 in combination with docetaxel in MC38 syngeneic model Tumor growth (%) → CAN04 blocks both IL-1α and IL-1β and has ADCC activity → CAN04 increase efficacy of docetaxel 50 → Control antibody blocking IL-1β only did not
Slide 8: Combination data in NSCLC show promising efficacy
Combination data in NSCLC show promising efficacy → CAN04 in combination with gem/cis in 1st line chemotherapy → 13* of 27 evaluable patients with non-sq non-small cell lung cancer (NSCLC) showed objective response including 1 complete response (48% vs historical control data 22-28%) → No major side
Slide 9: Positive data in pancreatic cancer
Benefit beyond progression Positive data in pancreatic cancer 200 150 Percent response CAN04 in combination with gem/abraxane in 1st line : (RECIST 1.1) • Durable responses observed (median DOR 6.8 mo, 27% response rate) 100 • Important finding of pseudoprogression-like response in 5 (15%) 50 patien
Slide 10: CAN04/GN in PDAC safety summary and benchmark
CAN04/GN in PDAC safety summary and benchmark Gem/Abraxane CANFOUR FOLFIRINOX Grade 3 or higher AEs (von Hoff) CAN04/GN (Conroy 2011) N=421 N=36 N=171 • G-CSF is an approved therapy to Neutropenia 38% 67% 46% counteract neutropenia. G-CSF Febrile neutropenia 3% 17% 5% was not used proac
Slide 11: Nadunolimab clinical development status
Nadunolimab clinical development status PDAC: planning and preparations for late stage development; data update initial cohort (33 pat) Q4 2021 and extension group (40pat) during H1 2022 NSCLC: Start of second part in non-squamous NSCLC followed by late stage preparations; data update during H1 2022
Slide 12: CAN10 – New development project
CAN10 – New development project → IL1RAP binding antibody potently blocking IL-1, IL-33 and IL-36 → Unique anti-inflammatory activity observed in different mouse models (myocarditis, psoriasis, inflammation) → Development focusing on unmet medical need in systemic sclerosis and myocarditis. Disease
Slide 13: Cantargia reached several milestones and have several value inflection points in near future
Cantargia reached several milestones and have several value inflection points in near future Newsflow over next 6-9 months Nadunolimab (CAN04) → New results PDAC, NSCLC and Keytruda combination → Upcoming trials PDAC and NSCLC → New preclinical and translational results → New clinical trials (FPI) •
Slide 14: Cantargia highlights
Cantargia highlights UNIQUE IMMUNOTHERAPY ANTIBODY CAN04 IN PHASE IIA CLINICAL DEVELOPMENT • First in class antibody with broader MOA than competitors • Positive interim data in pancreatic cancer and NSCLC VISION OF BECOMING AN IMPORTANT PART IN FUTURE CANCER TREATMENTS • Combination therapy strateg